Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience

<b>:</b> CDK4/6<b> </b>inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Michela Palleschi, Roberta Maltoni, Sara Ravaioli, Alessandro Vagheggini, Francesca Mannozzi, Francesca Fanini, Francesca Pirini, Maria Maddalena Tumedei, Eleonora Barzotti, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta, Paola Possanzini, Anna Fedeli, Annalisa Curcio, Mattia Altini, Ugo De Giorgi, Andrea Rocca, Sara Bravaccini
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2020-08-01
Colecção:Diagnostics
Assuntos:
advanced breast cancer
CDK4/6 inhibitors
Ki67
PR.
Acesso em linha:https://www.mdpi.com/2075-4418/10/8/573
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados